{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE347nnn/GSE347031/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Mus musculus"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE347031"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Therapeutic HPV16 E7 Vaccination with CD137 Agonism Induces Tumour Regression and Durable Immunity in Mice","description":"Therapeutic HPV16 E7 vaccination was evaluated in the syngeneic TC-1 tumour model in female C57BL/6 mice. Bulk RNA sequencing was performed on pooled, non-adherent mononuclear cell-enriched fractions prepared from subcutaneous tumour samples. The dataset compares PBS or vehicle controls, MPLA-adjuvanted wild-type E7 vaccination, MPLA-adjuvanted recombinant overlapping peptide E7 (ROP-E7) vaccination, anti-CD137 (4-1BB) agonism, and ROP-E7 plus anti-CD137 combination therapy. The study was designed to characterise treatment-associated changes in tumour immune and stromal transcriptional signatures.","dates":{"publication":"2026/09/25"},"accession":"GSE347031","cross_references":{"GSM":["GSM10044577","GSM10044576","GSM10044578","GSM10044573","GSM10044572","GSM10044575","GSM10044574","GSM10044571","GSM10044570","GSM10044569"],"GPL":["24247"],"GSE":["347031"],"taxon":["Mus musculus"]}}